AstraZeneca的强劲收入提高了FTSE 100,而其他公司的结果则好坏参半。 AstraZeneca's strong earnings boost FTSE 100, while other companies show mixed results.

AstraZeneca报告了2025年前半年的强劲成果,收入上升9.5%,税前利润上升26%。 AstraZeneca reported strong first-half 2025 results, with revenue up 9.5% and pretax profit up 26%. 巴克莱公司还提高了收入,并宣布了1bn英镑的股回购。 Barclays also boosted earnings and announced a £1bn share buyback. 然而,尽管销售额增加,Greggs的利润却下降了14%。 However, Greggs saw a 14% drop in profit despite higher sales. 富时 100 指数周二上涨 0.53%，受到积极的收益报告和阿斯利康提振的提振。 The FTSE 100 index rose 0.53% on Tuesday, buoyed by positive earnings reports and the AstraZeneca boost. 保健部门的结果好坏参半,AstraZeneca公司取得了主要成绩,而诺沃·诺迪斯克等其他公司的业绩则不佳。 The healthcare sector saw mixed results, with AstraZeneca leading gains while other companies like Novo Nordisk underperformed.